Arrowhead Pharmaceuticals To Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE And ARO-ALK7, Into Clinical Studies After They Demonstrated The Potential To Reduce Body Weight And Fat Mass With A Novel Mechanism Of Action That May Lead To Improved Preservation Of Lean Muscle Mass Compared To Currently Approved Obesity Therapies
Portfolio Pulse from Benzinga Newsdesk
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced plans to advance two new RNAi-based obesity candidates, ARO-INHBE and ARO-ALK7, into clinical studies. These candidates have shown potential in preclinical studies to reduce body weight and fat mass while preserving lean muscle mass. Arrowhead will submit clinical trial applications by the end of 2024 and aims to start clinical studies in early 2025.
August 14, 2024 | 5:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Arrowhead Pharmaceuticals is advancing two new RNAi-based obesity candidates, ARO-INHBE and ARO-ALK7, into clinical studies. These candidates have shown promising preclinical results in reducing body weight and fat mass while preserving lean muscle mass. Clinical trial applications will be submitted by the end of 2024, with studies starting in early 2025.
The announcement of advancing new obesity candidates into clinical studies is likely to positively impact Arrowhead Pharmaceuticals' stock price in the short term. The promising preclinical results and the novel mechanism of action could attract investor interest. The timeline for clinical trials adds a clear roadmap for future developments.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100